-+ 0.00%
-+ 0.00%
-+ 0.00%

Immuneering reports preclinical data supporting atebimetinib combinations in pancreatic cancer

PUBT·11/18/2026 12:33:33
Listen to the news
Immuneering reports preclinical data supporting atebimetinib combinations in pancreatic cancer
  • Immuneering on Nov. 18, 2026, reported preclinical findings supporting atebimetinib combinations with targeted therapies for pancreatic cancer.
  • Results showing enhanced activity with KRAS and PRMT5 inhibitors will be presented Nov. 19, 2026, at the EORTC-NCI-AACR Symposium.
  • Phase 2 results presented at ASCO in June showed long survival and favorable tolerability with atebimetinib combined with chemotherapy.
  • The Phase 3 MAPKeeper 301 trial is evaluating atebimetinib with modified chemotherapy against standard chemotherapy in previously untreated pancreatic cancer patients.
  • A recently announced Astellas collaboration will evaluate atebimetinib with CLDN18.2-targeted agents in two clinical trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180730PRIMZONEFULLFEED9880090) on November 18, 2026, and is solely responsible for the information contained therein.